Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
NovoCure Ltd.
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Bristol-Myers Squibb
Bristol-Myers Squibb
Hoffmann-La Roche
NovoCure Ltd.
Bristol-Myers Squibb
Hoffmann-La Roche
American Regent, Inc.
Hoffmann-La Roche
University Hospital, Limoges
Eli Lilly and Company
EMD Serono
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Spanish Lung Cancer Group
National Cancer Institute (NCI)
BeiGene
Novartis
Alliance for Clinical Trials in Oncology
BeiGene
EMD Serono
Novartis
Samsung Bioepis Co., Ltd.
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Menoufia University
AstraZeneca
Hoffmann-La Roche
Bristol-Myers Squibb
Helsinn Healthcare SA
Helsinn Healthcare SA
AstraZeneca
Merck Sharp & Dohme LLC
Ono Pharmaceutical Co. Ltd
Akeso
Swiss Cancer Institute
University of Texas Southwestern Medical Center
Biocad
Hoffmann-La Roche
Pfizer